PE20210468A1 - Formulaciones de apixaban - Google Patents

Formulaciones de apixaban

Info

Publication number
PE20210468A1
PE20210468A1 PE2020000316A PE2020000316A PE20210468A1 PE 20210468 A1 PE20210468 A1 PE 20210468A1 PE 2020000316 A PE2020000316 A PE 2020000316A PE 2020000316 A PE2020000316 A PE 2020000316A PE 20210468 A1 PE20210468 A1 PE 20210468A1
Authority
PE
Peru
Prior art keywords
apixaban formulations
apixaban
formulations
micromole
prophylaxis
Prior art date
Application number
PE2020000316A
Other languages
English (en)
Inventor
Jatin Patel
Charles Frost
Jingpin Jia
Chandra Vema-Varapu
Original Assignee
Bristol Myers Squibb Holdings Ireland
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20210468(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland, Pfizer filed Critical Bristol Myers Squibb Holdings Ireland
Publication of PE20210468A1 publication Critical patent/PE20210468A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a composiciones que comprenden particulas de apixaban cristalianas que tienen una D90 igual a, o menor que, 89 micromol, y un portador farmaceuticamente aceptable, que son substancialmente equivalentes y que pueden ser utilizadas para el tratamiento y/o la profilaxis de los transtornos tromboembolicos.
PE2020000316A 2010-02-25 2011-02-24 Formulaciones de apixaban PE20210468A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30805610P 2010-02-25 2010-02-25
PCT/US2011/025994 WO2011106478A2 (en) 2010-02-25 2011-02-24 Apixaban formulations

Publications (1)

Publication Number Publication Date
PE20210468A1 true PE20210468A1 (es) 2021-03-08

Family

ID=43901603

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2015002402A PE20160042A1 (es) 2010-02-25 2011-02-24 Formulaciones de apixaban
PE2012001362A PE20130378A1 (es) 2010-02-25 2011-02-24 Formulaciones de apixaban
PE2020000316A PE20210468A1 (es) 2010-02-25 2011-02-24 Formulaciones de apixaban

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2015002402A PE20160042A1 (es) 2010-02-25 2011-02-24 Formulaciones de apixaban
PE2012001362A PE20130378A1 (es) 2010-02-25 2011-02-24 Formulaciones de apixaban

Country Status (31)

Country Link
US (5) US9326945B2 (es)
EP (7) EP3662899A1 (es)
JP (4) JP5846647B2 (es)
KR (4) KR20170126016A (es)
CN (3) CN109602716A (es)
AU (1) AU2011220775B2 (es)
BR (1) BR112012021337A8 (es)
CA (1) CA2791171C (es)
CO (1) CO6640207A2 (es)
CY (5) CY1117434T1 (es)
DK (5) DK3017811T3 (es)
ES (5) ES2758031T3 (es)
HK (5) HK1180248A1 (es)
HR (5) HRP20160179T1 (es)
HU (4) HUE027168T2 (es)
IL (3) IL309564A (es)
IN (1) IN2012DN06587A (es)
LT (4) LT3017811T (es)
MX (3) MX2012009244A (es)
NZ (1) NZ601738A (es)
PE (3) PE20160042A1 (es)
PL (5) PL3251660T3 (es)
PT (5) PT2538925E (es)
RS (5) RS59576B1 (es)
RU (1) RU2685724C2 (es)
SG (2) SG182750A1 (es)
SI (5) SI3257500T1 (es)
SM (1) SMT201600049B (es)
TR (1) TR201903195T4 (es)
WO (1) WO2011106478A2 (es)
ZA (1) ZA201205807B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170126016A (ko) 2010-02-25 2017-11-15 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 아픽사반 제제
US20150018386A1 (en) * 2012-03-06 2015-01-15 Cadila Healthcare Limited Amorphous form of apixaban, process of preparation and compositions thereof
WO2013174498A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
NZ630763A (en) 2012-09-26 2017-01-27 Pfizer Apixaban liquid formulations
CN102908324A (zh) * 2012-10-31 2013-02-06 南京正科制药有限公司 一种阿哌沙班片
EP2752414A1 (en) 2013-01-04 2014-07-09 Sandoz AG Crystalline form of apixaban
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
WO2014203275A2 (en) * 2013-06-18 2014-12-24 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
CN103830199A (zh) * 2014-03-24 2014-06-04 重庆东得医药科技有限公司 含阿哌沙班的药用制剂及其制备方法
CN104316637B (zh) * 2014-10-30 2016-08-17 江苏宝众宝达药业有限公司 高效液相色谱法测定阿哌沙班清洗残留量
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
CA2976441A1 (en) * 2015-05-08 2016-11-17 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
EP3380083A1 (en) 2015-11-26 2018-10-03 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
CN106913528A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 阿哌沙班微丸及其制备方法
WO2017121340A1 (zh) * 2016-01-12 2017-07-20 广东东阳光药业有限公司 阿哌沙班固体组合物及其制备方法
EP3195860A1 (de) * 2016-01-22 2017-07-26 STADA Arzneimittel AG Verfahren zur herstellung eines apixaban-granulates
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
WO2017182908A1 (en) * 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Pharmaceutical compositions of apixaban
EP3243505A1 (en) 2016-05-13 2017-11-15 Zaklady Farmaceutyczne Polpharma SA A pharmaceutical composition comprising amorphous apixaban
CN106822006B (zh) * 2016-06-08 2020-08-28 北京普德康利医药科技发展有限公司 一种阿哌沙班片及其制备方法
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
CN109069502B (zh) * 2016-09-24 2021-08-06 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
CN106420651B (zh) * 2016-09-28 2019-03-08 乐普药业股份有限公司 一种阿哌沙班片的制备方法
US11510909B2 (en) 2017-02-17 2022-11-29 Unichem Laboratories Ltd. Pharmaceutical composition of apixaban
WO2019103092A1 (ja) 2017-11-27 2019-05-31 三菱ケミカル株式会社 ゴム含有グラフト重合体、ゴム含有グラフト重合体含有樹脂組成物およびその成形体
KR20190075566A (ko) 2017-12-21 2019-07-01 전자부품연구원 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법
TR201722523A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar
CN108236604A (zh) * 2018-02-07 2018-07-03 中国药科大学 阿哌沙班柔性脂质体
CA3097176A1 (en) 2018-04-16 2019-10-24 Bristol-Myers Squibb Company Apixaban formulations
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
KR20210044245A (ko) 2018-08-14 2021-04-22 지앙수 헨그루이 메디슨 컴퍼니 리미티드 주사가능 약학 조성물 및 이의 제조 방법
EP3666773A1 (en) 2018-12-11 2020-06-17 KRKA, D.D., Novo Mesto Process for preparing apixaban
EP3669866A1 (en) 2018-12-19 2020-06-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apixaban
CN111377915B (zh) * 2018-12-30 2023-10-24 鲁南制药集团股份有限公司 一种吡唑并-吡啶酮化合物晶型d
CN109464415B (zh) * 2019-01-09 2021-08-17 常州恒邦药业有限公司 阿哌沙班药物组合物及其制备方法
CN111214442B (zh) * 2020-02-13 2021-12-10 山东百诺医药股份有限公司 一种阿哌沙班共微粉化物
CN111494326A (zh) * 2020-04-11 2020-08-07 南京正大天晴制药有限公司 一种阿哌沙班片及其制备方法
WO2022115052A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Improved wet granulation processes for apixaban comprising formulations
WO2022150030A2 (en) 2021-01-08 2022-07-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet of apixaban
TR202100250A2 (tr) 2021-01-08 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren fi̇lm kapli tablet
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
EP4378454A1 (en) 2022-12-02 2024-06-05 Zerion Pharma Aps Solid pharmaceutical composition comprising apixaban and beta-lactoglobulin and process for preparing the composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
KR100628407B1 (ko) 1998-12-23 2006-09-26 브리스톨-마이어스 스퀴브 파마 컴파니 Ｘａ 인자 억제제로서의 질소 함유 헤테로비시클릭 화합물
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CH1427415H1 (de) * 2001-09-21 2023-12-21 Bristol Myers Squibb Holdings Ireland Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
US20070025991A1 (en) * 2003-03-19 2007-02-01 Charalabos Pothoulakis Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US7434502B2 (en) 2004-07-21 2008-10-14 Husqvarna Outdoor Products Inc. Bar knob with cam-operated locking mechanism
US20060016084A1 (en) * 2004-07-24 2006-01-26 Ching-Lin Liao Laser-Based datum instrument
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
EP1951197A4 (en) 2005-11-10 2011-12-21 Alphapharm Pty Ltd METHOD OF CHECKING THE PARTICLE SIZE
US20070259913A1 (en) 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
CN101516355A (zh) * 2006-09-12 2009-08-26 葛兰素集团有限公司 包括多个含有因子Xa抑制剂的微型片剂的药物组合物
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
CA2684722A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP2291233B1 (en) * 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
JP2011527668A (ja) 2008-07-11 2011-11-04 ビーエーエスエフ ソシエタス・ヨーロピア 形態改質剤としての両親媒性タンパク質
US20100018486A1 (en) * 2008-07-22 2010-01-28 Hung-Tao Liu Cathode energy fuel-saving device
EP2424521A4 (en) * 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
WO2010147978A1 (en) 2009-06-16 2010-12-23 Pfizer Inc. Dosage forms of apixaban
KR20170126016A (ko) * 2010-02-25 2017-11-15 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 아픽사반 제제
US9211258B2 (en) * 2010-03-10 2015-12-15 Lupin Limited Rifaximin ready-to-use suspension

Also Published As

Publication number Publication date
RS54559B1 (en) 2016-06-30
RU2685724C2 (ru) 2019-04-23
LT3246021T (lt) 2020-02-10
PL2538925T3 (pl) 2016-06-30
RS59810B1 (sr) 2020-02-28
HUE047140T2 (hu) 2020-04-28
HK1243947B (zh) 2020-06-19
US20170202825A1 (en) 2017-07-20
KR20210124532A (ko) 2021-10-14
PT3246021T (pt) 2020-02-21
CY1122382T1 (el) 2021-01-27
ES2767848T3 (es) 2020-06-18
DK3251660T3 (da) 2019-11-25
HK1180248A1 (zh) 2013-10-18
BR112012021337A2 (pt) 2016-10-25
PL3246021T3 (pl) 2020-04-30
JP6033945B2 (ja) 2016-11-30
CN102770126A (zh) 2012-11-07
KR20170126016A (ko) 2017-11-15
SI2538925T1 (sl) 2016-04-29
PL3251660T3 (pl) 2020-02-28
PE20160042A1 (es) 2016-01-28
HUE043932T2 (hu) 2019-09-30
HUE047139T2 (hu) 2020-04-28
LT3257500T (lt) 2019-12-10
HRP20192064T1 (hr) 2020-02-21
CY1121597T1 (el) 2020-05-29
KR101796300B1 (ko) 2017-11-10
HRP20160179T1 (hr) 2016-04-08
EP3662899A1 (en) 2020-06-10
CN109602716A (zh) 2019-04-12
JP5846647B2 (ja) 2016-01-20
HK1243946A1 (zh) 2018-07-27
CN109602713A (zh) 2019-04-12
US20170202824A1 (en) 2017-07-20
ES2758031T8 (es) 2020-08-05
PT3017811T (pt) 2019-03-21
EP3257500B1 (en) 2019-10-16
LT3251660T (lt) 2019-12-10
EP3251660A1 (en) 2017-12-06
EP3643301A1 (en) 2020-04-29
JP6577980B2 (ja) 2019-09-18
RS58699B1 (sr) 2019-06-28
MX353145B (es) 2017-12-20
WO2011106478A3 (en) 2012-04-12
BR112012021337A8 (pt) 2016-11-29
PL3017811T3 (pl) 2019-06-28
RS59593B1 (sr) 2020-01-31
PT3257500T (pt) 2019-11-26
HRP20190430T8 (hr) 2019-06-14
KR20230149861A (ko) 2023-10-27
LT3017811T (lt) 2019-02-25
MX364938B (es) 2019-05-15
ES2714363T3 (es) 2019-05-28
CA2791171C (en) 2017-08-29
JP2017039768A (ja) 2017-02-23
ES2758031T3 (es) 2020-05-04
DK2538925T3 (en) 2016-03-14
EP2538925A2 (en) 2013-01-02
HRP20200046T1 (hr) 2020-03-20
CA2791171A1 (en) 2011-09-01
EP3246021A1 (en) 2017-11-22
ES2757603T3 (es) 2020-04-29
WO2011106478A2 (en) 2011-09-01
PT2538925E (pt) 2016-03-18
EP3017811B1 (en) 2018-12-05
EP3251660B1 (en) 2019-10-16
EP3257500A1 (en) 2017-12-20
ES2562279T3 (es) 2016-03-03
CY1122384T1 (el) 2021-01-27
CY1122529T1 (el) 2021-01-27
RS59576B1 (sr) 2019-12-31
JP2013521226A (ja) 2013-06-10
SI3017811T1 (sl) 2019-04-30
DK3246021T3 (da) 2020-02-03
SI3251660T1 (sl) 2019-12-31
SMT201600049B (it) 2016-04-29
JP2017226679A (ja) 2017-12-28
PT3251660T (pt) 2019-12-02
US20160243101A1 (en) 2016-08-25
SI3257500T1 (sl) 2019-12-31
JP2016065086A (ja) 2016-04-28
NZ601738A (en) 2014-02-28
JP6192078B2 (ja) 2017-09-06
HRP20192069T1 (hr) 2020-02-07
EP3017811A1 (en) 2016-05-11
HRP20190430T1 (hr) 2019-05-17
SI3246021T1 (sl) 2020-03-31
US20200375968A1 (en) 2020-12-03
HK1224216A1 (zh) 2017-08-18
HUE027168T2 (en) 2016-10-28
EP2538925B1 (en) 2015-12-16
DK3017811T3 (en) 2019-04-01
CY1117434T1 (el) 2017-04-26
IN2012DN06587A (es) 2015-10-23
KR20130009753A (ko) 2013-01-23
US20130045245A1 (en) 2013-02-21
IL309564A (en) 2024-02-01
MX2012009244A (es) 2012-08-23
EP3246021B1 (en) 2019-11-13
IL251991A0 (en) 2017-06-29
ZA201205807B (en) 2016-01-27
TR201903195T4 (tr) 2019-03-21
AU2011220775B2 (en) 2015-09-24
PL3257500T3 (pl) 2020-03-31
HK1243945B (zh) 2020-06-19
SG182750A1 (en) 2012-08-30
CO6640207A2 (es) 2013-03-22
IL221064A0 (en) 2012-09-24
RU2012140690A (ru) 2014-03-27
PE20130378A1 (es) 2013-03-30
AU2011220775A1 (en) 2012-09-13
SG10201501349VA (en) 2015-04-29
US9326945B2 (en) 2016-05-03
DK3257500T3 (da) 2019-11-25

Similar Documents

Publication Publication Date Title
PE20210468A1 (es) Formulaciones de apixaban
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
ECSP12012148A (es) Composiciones sólidas
CA2818187C (en) Bromodomain inhibitors and uses thereof
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
IN2014DN09804A (es)
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX348823B (es) Formulaciones estables de linaclotida.
TN2011000327A1 (en) Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
MX2013010511A (es) Inhibidores triciclicos de girasa.
MX344435B (es) Compuestos antitromboticos.
MX2012001660A (es) Formulaciones que contienen linaclotida para adminstracion oral.
MX2013004162A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1.
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
IN2014MN02245A (es)
MX2015008187A (es) Inhibidores de alk deuterados.
IN2012DN00763A (es)
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
CR20120632A (es) Composiciones sòlidas
TN2013000137A1 (en) Pharmaceutical compositions containing a dgat 1 inhibitor